Compounded GLP-1 medications, explained properly

If you are considering a telehealth weight-care programme — Syra Rx or any other — this is the background that makes the rest of it legible. It is not complicated, but it is routinely glossed over, and understanding it changes what questions you ask.

What compounding actually is

Compounding is the practice of a licensed pharmacy preparing a medication to meet a specific patient’s needs. It is a long-established part of pharmacy: making a liquid version for someone who cannot swallow tablets, preparing a formulation without an allergen, adjusting a dose that is not commercially available.

Two regulatory categories exist. 503A pharmacies compound for individual patients against individual prescriptions. 503B outsourcing facilities compound at larger scale and face more manufacturing oversight.

Why compounded GLP-1 is not FDA-approved

There is a second confusion worth clearing up. Compounding pharmacies may be registered with the FDA and subject to inspection — but facility registration is not drug approval, and the FDA has written to companies for implying otherwise. If a page tells you a pharmacy is “FDA approved”, that phrase does not describe anything real.

What changed: a timeline

The reason compounded GLP-1 became widely available, and why that is now narrowing, comes down to drug shortages.

When	What happened
2022–2024	Demand for GLP-1 medications outstripped supply. Both drugs went on the FDA shortage list, which opened a legal pathway for compounding pharmacies to prepare copies.
December 2024	FDA declared the tirzepatide shortage resolved.
February 2025	FDA declared the semaglutide shortage resolved, removing the pathway that had allowed compounded copies at scale.
2025	Enforcement discretion periods ended. Warning letters began going to companies selling compounded GLP-1 products.
February 2026	FDA announced intended enforcement against mass-marketed, non-FDA-approved compounded GLP-1 products and misleading claims.
March 2026	FDA announced warning letters to 30 telehealth companies over false or misleading compounded GLP-1 marketing. These letters name the telehealth company, not just the pharmacy.
April 2026	FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound them from bulk substances. Public comment ran to 29 June 2026.

As of autumn 2026, the 503B bulks proposal was still a proposal pending final determination. If finalised, it would close one of the two routes telehealth companies have used.

Is compounded semaglutide still legal?

Not flatly illegal, no. Patient-specific compounding by a 503A pharmacy against a valid prescription can still be appropriate where federal and state requirements are met — notably the requirement that a compounded product not be “essentially a copy” of an available approved drug. The FDA’s general position is that compounded drugs should be used by patients whose medical needs cannot be met by an FDA-approved drug.

What has gone is the shortage-era justification for large-scale compounded GLP-1 programmes. The practical consequence for you as a patient is simply that this is a tightening area, and a programme available today may change.

The “personalised” formulation problem

Similarly, sublingual drops and dissolving tablet versions of these medications exist in the compounded market and have never been studied in clinical trials. The approved products are injectables, with an approved oral semaglutide tablet. Novel routes of administration are not equivalent simply because the active ingredient is the same.

Reported adverse events

The FDA has received a significant number of adverse event reports linked to compounded semaglutide and compounded tirzepatide, with reported problems including severe nausea, vomiting, hypoglycaemia, infections and hospitalisations. Adverse event reports do not establish causation and come from a large user base. But they are a reason to follow dosing instructions exactly and to report problems rather than endure them.

What to ask before starting any compounded programme

• Is what I am being prescribed compounded, or an FDA-approved brand-name product?
• Which pharmacy prepares it, and is it state-licensed? 503A or 503B?
• What exactly is in the formulation — is anything combined with the active ingredient?
• What route of administration, and has that route been studied?
• Is potency tested, and by whom?
• What happens to my supply if the regulatory position changes mid-programme?

A provider who answers these clearly is a good sign. A page that will not address them is a bad one.

Safety information that applies regardless

One consideration is specific to compounded products: because the formulation has not been reviewed by the FDA, you are relying on the compounding pharmacy’s own standards for potency and consistency. That makes knowing which pharmacy prepared your medication, and whether it is state-licensed, more important than it would be with an approved product carrying a standardised label.

The balanced conclusion

Compounded medication is not inherently dangerous, and compounding pharmacies serve a real purpose. Equally, compounded GLP-1 is not the same product as the approved brand, the regulatory environment around it is actively tightening, and the marketing in this category has drawn direct federal enforcement attention. Both things are true. Go in with your eyes open, ask the questions above, and involve a clinician who knows your history.

Not medical or legal advice. Regulatory positions in this area change. Verify current status with primary sources and consult a qualified healthcare professional.